Sector News

Haemonetics Expands Executive Management Roles To Complement Global Growth Strategy

April 28, 2015
Life sciences
/PRNewswire/ – Haemonetics Corporation announced today expanded roles for two executives.  These changes are part of an ongoing plan to advance the Company’s global leadership in blood management solutions and to execute on strategies to enhance shareholder value.
 
Kent Davies, who joined the Company in 2014, is appointed to the new position of Chief Operating Officer, reporting directly to Brian Concannon, President and CEO.  In this expanded role, Mr. Davies will have overall accountability for the Company’s commercial, product development and product management focus across the entire portfolio and in all geographies. 
 
Byron Selman, who joined the Company upon the acquisition of Pall Corporation’s transfusion medicine business in 2012, is appointed to the position of President, Global Markets, reporting to Mr. Davies.  Mr. Selman will oversee the Company’s global commercial and market development efforts, with the exception of the Company’s commercial Plasma business. 
 
Mr. Concannon stated: “Haemonetics enters fiscal 2016 with good momentum, brought about by recent contract wins, new product innovations and launches, and a Comprehensive Blood Management Solutions (CBMS) offering that is gaining traction with customers.  These two management promotions will enhance our execution efforts and strategic focus in all of our markets, while leveraging our strengths in product management and product development.”
 
Source: Haemonetics

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach